Moreover, pritumumab binds to the ecto-domain of vimentin on the surface of cancer cells with no off-target effects or not impairing the function of normal vimentin [76,77], thus offering an opportunity for testing in ARSACS models. This evidence concerns the gene VIM and cancer.